DWM
TGTX icon

Darwin Wealth Management’s TG Therapeutics TGTX Stock Holding History

Darwin Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-325
Closed -$9.78K – 670
2025
Q1 		$9.78K Hold
325
– – ﹤0.01% 379
2024
Q4 		$9.78K Hold
325
– – ﹤0.01% 379
2024
Q3 		$7.6K Buy
+325
New +$7.1K ﹤0.01% 414
2020
Q2 		– Sell
-100
Closed – – 709
2020
Q1 		$0 Buy
+100
New +$1.26K ﹤0.01% 846

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Darwin Wealth Management's TGTX Position: Q2 2025 in Review

Darwin Wealth Management sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 325 shares — an estimated $9.78K sold.

Darwin Wealth Management first reported a position in TGTX in Q1 2020 and held it in 4 quarters. The position peaked at $9.78K in Q1 2025. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • Darwin Wealth Management reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Darwin Wealth Management sold 325 TG Therapeutics shares in Q2 2025, an estimated $9.78K.
  • Darwin Wealth Management first reported a position in TG Therapeutics in Q1 2020 and held it in 4 quarters.
  • Darwin Wealth Management's TG Therapeutics position peaked at $9.78K in Q1 2025.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Darwin Wealth Management's 13F filing for Q2 2025, filed 14 Aug 2025.